Lyell Immunopharma, Inc.
LYEL
Positions held
Your positionsLYEL isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $215.40M | Enterprise value | $57.90M | Trailing P/E | — | Forward P/E | -1.39 |
| PEG | — | Price / book | 0.88 | Beta | -0.03 | Dividend yield | 0.00% |
| Revenue growth | -50.0% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -11834.3% |
| Profit margin | 0.0% | ROE | -93.3% | ROA | -34.2% | Debt / equity | 0.20 |
| Current ratio | 5.36 | Free cash flow | -$72.81M | Analyst recommendation | buy | Mean target | $37.88 |
| 52w high | $45.00 | 52w low | $8.21 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | -1183425.0% | -2213050.0% | -1021866.7% | -248353.3% | -571212.5% | — |
| Net income | -$44.8M | -$24.2M | -$141M | -$38.8M | -$42.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$47.3M | -$44.3M | -$61.3M | -$37.3M | -$45.7M | — |
- Revenue +100% vs prior quarter ($0.0M vs $0.0M).
- Operating margin expanded to -1183425%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.1M | $0.1M | $84.7M |
| Op margin | -560080.6% | -361104.9% | -190006.2% | -220.9% |
| Net income | -$274M | -$343M | -$235M | -$183M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$202M | -$220M | -$247M | -$187M |
Headlines — watch
• [WARN · balance sheet] Lyell Immunopharma Files for Secondary Offering of Common Shares
News
2026-09-14 · Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
2026-08-06 · Lyell Immunopharma: Q2 Earnings Snapshot
2026-08-06 · Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
2026-08-06 · Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
2026-08-06 · Stifel Initiates Lyell Immunopharma at Buy With $36 Price Target
2026-07-22 · B. Riley Initiates Lyell Immunopharma at Buy With $44 Price Target
2026-07-13 · Lyell Immunopharma Files for Secondary Offering of Common Shares
Price (daily)
Full chart · RSI · MACD · patterns